To resolve such open questions, interventional studies using intranasal insulin (Schneider et al., 2022) or ghrelin administration (Malik, McGlone, Bedrossian, & Dagher, 2008) in patients with MDD would be necessary. The gene discussed is GHRL; the disease is major depressive disorder.